 |
 |
 |
 |
 |
 |
About Cellerant |
|
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company focuses on curative therapies for seriously ill patients. Cellerant is developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. And we are applying our expertise in hematopoietic ontogeny to identify novel drug targets and therapeutic antibodies aimed at cancer stem cells. |
Cellerant's Press Releases |
||
 |
|
May 14, 2012 Cellerant Announces Publication Demonstrating Significant Survival Benefits and Preclinical Proof of Concept with Myeloid Progenitors as Radiation Countermeasure |
|
|
February 21, 2012 Cellerant Therapeutics appoints Lowell E. Sears to board of directors. |
|
|
September 15, 2011 Cellerant Therapeutics Awarded Additional $16.7 Million Under Existing US Government Contract to Fund Development of CLT-008 for Acute Radiation Syndrome |
|
|
March 22, 2011 Cellerant Therapeutics Initiates a Phase I/II Clinical Trial of CLT-008 for Chemotherapy Induced Neutropenia in Acute Leukemia Patients |
|
||
|
|
|